A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.

ABSTRACT: The safety of daptomycin in infants under 1 year old remains uncertain. This study aimed to identify signals potentially associated with daptomycin use in this special population based on the Food and Drug Administration adverse event reporting system (FAERS). Real-world pharmacovigilance research was conducted on the FAERS database from Q1 2004 to Q2 2024. Disproportionality analyses, including reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN), were used to assess the strength of AEs signals for daptomycin. A subgroup analysis was conducted on the data from the past 5 years to further explore the association between AEs and daptomycin. A total of 96 AEs of daptomycin as the p

SUBMITTER: Ye L 

PROVIDER: S-EPMC12627487 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature